[Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]
Sign Up to like & getrecommendations! Published in 2018 at "Der Internist"
DOI: 10.1007/s00108-017-0362-5
Abstract: BACKGROUND Inhibition of platelet aggregation can reduce the rate of vascular events in patients with coronary artery disease, carotid artery stenosis and symptomatic peripheral arterial disease. The choice of platelet inhibitors in monotherapy and combination… read more here.
Keywords: patients coronary; cerebral peripheral; platelet inhibition; inhibition ... See more keywords
Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2017.12.055
Abstract: BACKGROUND Clopidogrel is used to pretreat patients with non-ST elevation acute coronary syndromes (NSTE-ACS), but prasugrel provides better platelet inhibition with improved outcome. However, switching from clopidogrel at the time of percutaneous coronary intervention (PCI)… read more here.
Keywords: switching clopidogrel; prasugrel; clopidogrel; platelet inhibition ... See more keywords
DRUG RELATED PLATELET INHIBITION: IS THERE A ROLE FOR REDUCTION OF CEREBRAL MICROEMBOLI IN TRANSCATHETER AORTIC VALVE IMPLANTATION PATIENTS?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)31813-3
Abstract: Whether non-thienopyridines may protect patients more efficiently from microembolic events during TAVI has not been investigated. We hypothesized that ticagrelor+ASA will reduce the number of microemboli towards the cerebral circulation during TAVI comparing to the… read more here.
Keywords: role reduction; platelet inhibition; drug related; inhibition role ... See more keywords
Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarct-prone early-morning hours
Sign Up to like & getrecommendations! Published in 2018 at "Platelets"
DOI: 10.1080/09537104.2018.1528347
Abstract: Abstract Aspirin is traditionally taken once daily in the morning and considered to be effective throughout the 24h interval. Cardiovascular events occur most frequently in the early morning, suggesting that these hours are critical in… read more here.
Keywords: platelet inhibition; aspirin intake; morning; early morning ... See more keywords
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION
Sign Up to like & getrecommendations! Published in 2022 at "Circulation: Cardiovascular Interventions"
DOI: 10.1161/circinterventions.121.011069
Abstract: Background: In randomized trials, cangrelor reduced periprocedural ischemic events related to percutaneous coronary intervention without increasing GUSTO severe bleeding. However, some antiplatelet agents have shown a differential treatment effect by body mass index (BMI). Methods:… read more here.
Keywords: cangrelor; platelet inhibition; cangrelor versus; obese patients ... See more keywords
Ticagrelor – toward more efficient platelet inhibition and beyond
Sign Up to like & getrecommendations! Published in 2018 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s152369
Abstract: Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS).… read more here.
Keywords: platelet inhibition; ticagrelor; ticagrelor toward; efficient platelet ... See more keywords
Monitoring antiplatelet therapy: where are we now?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Medicine"
DOI: 10.2459/jcm.0000000000001406
Abstract: Single antiplatelet therapy represents the cornerstone of thrombosis prevention in atherosclerotic cardiovascular disease. Dual antiplatelet therapy (DAPT), consisting of aspirin plus a P2Y12 inhibitor, is the standard of care for patients with acute coronary syndrome… read more here.
Keywords: platelet inhibition; therapy monitoring; monitoring antiplatelet; antiplatelet therapy ... See more keywords
Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: comparing results of the VerifyNow P2Y12 assay to thromboelastography with platelet mapping.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of neurosurgery"
DOI: 10.3171/2017.6.jns17535
Abstract: OBJECTIVEInhibition of platelet aggregation is vital to preventing thromboembolic complications related to stent placement in endovascular neurosurgery, but excessive inhibition potentiates hemorrhagic complications. Recent evidence suggests an ideal inhibition range of 70-150 P2Y12 response units… read more here.
Keywords: platelet inhibition; inhibition; pru; platelet mapping ... See more keywords
Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial
Sign Up to like & getrecommendations! Published in 2022 at "Cardiology Journal"
DOI: 10.5603/cj.a2022.0049
Abstract: Background Morphine reduces absorption and delays action onset of potent oral P2Y12 receptor inhibitors in patients with ST-segment elevation myocardial infarction (STEMI). We sought to determine the differential effects of fentanyl compared to morphine on… read more here.
Keywords: platelet; platelet inhibition; patients segment; segment elevation ... See more keywords